Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin in T2DM inadequately controlled on metformin and sitagliptin
NCT02036515Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ertugliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Hemoglobin A1C at 26 weeks, Percentage of Participants Experiencing An Adverse Event at 54 weeks and 1 more. Started Mar 2014; status: completed.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02036515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036515.